Equities

Shanghai MicroPort Endovascular MedTech Group Co Ltd

688016:SHH

Shanghai MicroPort Endovascular MedTech Group Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)108.01
  • Today's Change-0.87 / -0.80%
  • Shares traded2.35m
  • 1 Year change-15.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shanghai MicroPort Endovascular MedTech Group Co Ltd, formerly Shanghai MicroPort Endovascular MedTech Co Ltd, is a China-based company principally engaged in the research and development, production and sales of aortic and peripheral vascular interventional medical devices. The Company's main products include the aortic stent graft system for aortic minimally invasive interventional procedures, the intraoperative stent system for open surgery, as well as the peripheral vascular stent system and peripheral balloon dilatation catheters for the treatment of peripheral vascular diseases. The Company mainly distributes its products to the domestic market.

  • Revenue in CNY (TTM)1.27bn
  • Net income in CNY657.34m
  • Incorporated2012
  • Employees908.00
  • Location
    Shanghai MicroPort Endovascular MedTech Group Co LtdNo. 1, Lane 3399, Kangxin HighwayPudong New AreaSHANGHAI 201318ChinaCHN
  • Phone+86 2 138139300
  • Fax+86 2 133750026
  • Websitehttps://www.endovastec.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
688016:SHH since
announced
Transaction
value
Optimum Medical LtdAnnounced02 Jul 202402 Jul 2024Announced10.44%65.00m
Data delayed at least 15 minutes, as of Nov 21 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shinva Medical Instrument Co Ltd10.12bn692.34m11.17bn8.21k13.031.49--1.101.411.4118.3112.340.67752.204.961,232,589.004.724.639.1410.7625.6224.226.966.120.8303--0.163715.917.87-0.534230.7895.70-5.9061.86
Qingdao Haier Biomedical Co Ltd2.24bn358.01m11.43bn2.64k31.902.66--5.111.131.137.0413.530.40185.126.38848,473.706.5611.498.2915.2247.8249.9816.3425.202.53--0.031626.53-20.3622.07-32.4128.9420.64--
Shandong Weigao Orthopaedic Devce Co Ltd1.28bn154.60m11.60bn2.21k75.162.96--9.030.38580.38583.209.780.25240.67144.03581,131.603.1410.973.9513.6962.4077.3312.4327.083.62--0.009617.90-30.551.17-79.36-19.11-4.31--
Shanghai Runda Medical Technology Co Ltd8.43bn40.27m12.13bn3.32k300.952.83--1.440.06730.067313.617.170.58314.191.492,543,990.001.184.783.1312.8625.9427.132.036.361.013.040.560912.43-12.848.93-34.580.85143.881.03
Beijing Wandong Medical Technolgy Co Ltd1.40bn184.09m12.18bn1.06k66.102.57--8.670.2620.2622.006.740.26472.764.011,325,746.003.505.303.916.2138.8345.2113.2216.469.48--0.017935.8210.305.327.514.22-16.665.39
Shanghai MicroPort Edvcl MdTch Grp CoLtd1.27bn657.34m13.42bn908.0020.013.45--10.585.445.4410.5931.540.3711.336.511,396,816.0019.0017.6821.5519.4374.5176.6051.2142.255.49--0.006744.4632.4338.7237.9840.2850.18--
Micro-Tech Nanjing Co Ltd2.68bn550.49m13.96bn2.40k25.283.74--5.212.942.9414.3019.860.61181.656.801,114,222.0012.8710.7415.2612.8266.0463.0421.0419.373.99--0.018335.4321.7821.2046.9920.3239.33--
Shanghai Haohai Biological Tech Co Ltd2.75bn430.21m13.98bn2.16k35.732.76--5.091.861.8611.8924.070.38331.607.601,272,966.005.604.846.605.5068.9772.0414.6116.363.71--0.069736.8624.5911.24130.580.076211.96--
Sansure Biotech Inc1.41bn259.42m14.05bn2.01k53.921.91--9.990.44750.44752.4412.620.16670.8782.03701,473.702.5226.742.7930.9776.4367.4715.1242.017.45--0.058322.40-84.3927.12-81.22121.8964.08--
Data as of Nov 21 2024. Currency figures normalised to Shanghai MicroPort Endovascular MedTech Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

14.06%Per cent of shares held by top holders
HolderShares% Held
Nuode Asset Management Co., Ltd.as of 24 Jun 20244.59m3.73%
Harvest Fund Management Co., Ltd.as of 24 Jun 20243.52m2.86%
ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 20242.31m1.88%
Caitong Fund Management Co., Ltd.as of 24 Jun 20242.27m1.85%
Hwabao WP Fund Management Co., Ltd.as of 30 Sep 20231.52m1.23%
E Fund Management Co., Ltd.as of 24 Jun 2024752.39k0.61%
CITIC Securities Co., Ltd. (Invt Port)as of 24 Jun 2024725.84k0.59%
Bosera Asset Management Co., Ltd.as of 30 Jun 2024557.05k0.45%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024542.04k0.44%
China Asset Management Co., Ltd.as of 30 Jun 2024528.27k0.43%
More ▼
Data from 30 Jun 2024 - 11 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.